Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02547389 |
|
Recruitment Status :
Completed
First Posted : September 11, 2015
Last Update Posted : September 11, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Improving medical compliance and health-related quality of life (HRQoL) among people with epilepsy (PWE) has become the focus of various treatment programs and behavioral interventions which continue to be challenging to both patients and health care professionals.
In order to design an effective intervention on the management of epilepsy, the drug management of epilepsy by community health workers was evaluated.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Epilepsy | Behavioral: Community support group Other: Printed material Supported | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 144 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Supportive Care |
| Official Title: | Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy: Randomized Controlled Trial |
| Study Start Date : | January 2014 |
| Actual Primary Completion Date : | April 2015 |
| Actual Study Completion Date : | June 2015 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Intervention Group (IG)
IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
|
Behavioral: Community support group |
|
Control Group (CG)
Patients in the CG were supplied with only printed epilepsy educational module
|
Other: Printed material Supported |
- Compliance with taking prescribed medications [ Time Frame: 12 months ]Assessment of compliance with taking medications at regularly scheduled intervals
- Seizure frequency per month [ Time Frame: change from baseline to 12 months in number of seizures per month assessed by patients diary ]Assessment of seizure count accuracy by assessing total number of seizures reported per month
- Quality of Life (Malay Quality of Life in Epilepsy Inventory-30) [ Time Frame: change from baseline to 12 months in quality of life assessed by Malay Quality of Life in Epilepsy Inventory-30 ]Malay Quality of Life in Epilepsy Inventory-30, to assess for overall change in quality of life measures
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible participants must have a definitive diagnosis of epilepsy for at least 6 months, based on the clinical judgement of the investigators. Epilepsy is defined by two or more unprovoked seizures. Clinical history, electroencephalography, and imaging data are all instrumental in rendering a formal decision. The seizure type, frequency, or severity are not criteria for exclusion, although this information will be recorded.
- Patients must have a seizure frequency of at least two seizures in a 6 month period of time.
- Patients must be on at least one anti-epileptic medication.
- Patients must be able to report seizure frequency with either a paper or electronic diary.
- Patients must be able to read and understand either English or Hindi.
- Patients must be able to complete questionnaires and provide informed consent to this study.
Exclusion Criteria:
- A diagnosis of psychogenic nonepileptic seizures
- Severe depression, anxiety, or psychosis
- Recent problem with substance abuse.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02547389
| Principal Investigator: | Hitesh K Nayak | NMP Medical Research Institute | |
| Study Director: | Neha Sharma, PhD | Macmillan Research Group UK |
| Responsible Party: | NMP Medical Research Institute |
| ClinicalTrials.gov Identifier: | NCT02547389 |
| Other Study ID Numbers: |
nmp/22181 |
| First Posted: | September 11, 2015 Key Record Dates |
| Last Update Posted: | September 11, 2015 |
| Last Verified: | September 2015 |
|
Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases |

